Publications by authors named "K M Baird"

Assessing Fear of Birth Scale's (FOBS) psychometric properties in the perinatal period using multicountry data is a step toward effectively screen clinically significant fear of childbirth (FOC) in maternal healthcare settings. FOBS psychometric properties were analyzed in women in the perinatal period using data from Australia, Germany, Lithuania, Poland, and Portugal. FOBS' reliability, criterion (known group and convergent), concurrent, predictive, and clinical validity were analyzed.

View Article and Find Full Text PDF

Problem: Despite the significance of the perinatal period, postnatal care remains insufficient for optimising long-term health.

Background: The perinatal period is a vulnerable time in a woman's life-course health trajectory. Supporting transitions from hospital to primary care is essential to promote health and guide evidence-based follow-up care.

View Article and Find Full Text PDF

Background: The mistreatment of women during maternity care hinders quality care globally and deter women from seeking health services. To implement necessary actions, it is essential to explore instances of mistreatment, their factors and negative outcomes. This study explores the narratives of mistreatment experienced by women, its drivers, as well as the consequences of mistreatment.

View Article and Find Full Text PDF

The family Oceanitidae, formerly considered a subfamily of Hydrobatidae, includes all the small storm-petrels of the southern hemisphere. The ancestor-descendent relationships and evolutionary history of one of its genera, Oceanites, have been partially studied, yielding contrasting results. We revised the phylogenetic relationships of this group using Bayesian inference (BI) based on new sequence data of the mitochondrial gene Cytb and linear morphological measurements of all species and five subspecies-level taxa in Oceanites, including a new taxon from the Chilean Andes.

View Article and Find Full Text PDF
Article Synopsis
  • - Outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) are generally poor; however, the FDA approved Loncastuximab-teserine (Lonca) based on the LOTIS-2 trial results for those who have undergone at least two prior treatments.
  • - A retrospective study analyzed 187 patients from 21 US centers treated with Lonca, revealing a complete response rate of 14% and an overall response rate of 32%, indicating lower efficacy in a real-world setting compared to the original trial.
  • - Patients in this study had higher risk features, including bulky disease and high-grade B-cell histology, leading to poorer median event-free survival (2.1 months
View Article and Find Full Text PDF